Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL2421558 | 0.94 | KDM4E (0.52) | KDM4ELMNAHPGDHTTCYP3A4 | |
| SCHEMBL223649 | 0.85 | KCNH2 (0.46) | HTTALDH1A1MAPTKMT2A | |
| SCHEMBL223654 | 0.84 | KMT2A (0.46) | ALDH1A1SMN1; SMN2KMT2A | |
| Cyclohexane SCHEMBL2428515 | 0.83 | HRH3 (0.40) | CYP3A4 | |
| SCHEMBL220849 | 0.83 | HRH3 (0.38) | KDM4ELMNAHPGDHTTCYP3A4 | |
| SCHEMBL2428638 | 0.80 | HRH3 (0.38) | CYP3A4MAPTPOLB | |
| Trifluoroacetic Acid SCHEMBL444415 | 0.79 | KCNH2 (0.41) | HTTALDH1A1MAPTKMT2A | |
| SCHEMBL254047 | 0.79 | NPC1 (0.48) | KDM4EHPGDHTTMAPK1ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL223098 | 0.78 | KMT2A (0.41) | ALDH1A1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL222631 | 0.78 | RAB9A (0.47) | KDM4ECYP3A4ALDH1A1MAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2212282-B1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2011-09-21 | — | — | EP | disclosed |
| US-20100173897-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173897-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | HRH3, HRH4, CNR1 | KDM4E 1155/4885LMNA 3317/4885HPGD 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.